FMS

Business Context and Reporting Period

Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three and six months ended June 30, 2020
Business Overview: The world's largest kidney dialysis company, providing dialysis care, related services, and manufacturing health care products. Operations are segmented into North America, EMEA, Asia-Pacific, and Latin America.

Key Financial Metrics (Six Months Ended June 30, 2020)

Material Changes vs. Prior Period

• Revenue Growth: Driven by a 6% increase in health care services and an 8% increase in health care products. Growth was supported by same-market treatment increases, acquisitions, and higher organic revenue per treatment.
• Profitability Expansion: Operating income margin improved by 0.9 percentage points, primarily due to lower renal pharmaceutical costs, the suspension of the 2% Medicare sequestration (CARES Act), and reduced SG&A expenses (travel savings, prior-year legal settlements).
• Cash Flow Surge: Net cash from operating activities jumped to €2.9 billion (from €0.9 billion in 2019), largely due to U.S. federal relief funding (CARES Act) and advanced Medicare payments.
• Segment Performance:
  • North America: Strongest performer with operating income up 34% (€1,073M), driven by dialysis services and Care Coordination improvements.
  • EMEA: Operating income declined 24% (€179M) due to an impairment of a license held by a joint venture (VFMCRP) and reduced contingent consideration liability in the prior year.
  • Asia-Pacific: Operating income fell 15% (€140M) due to COVID-19 impacts on Care Coordination activities.
  • Latin America: Operating income increased 3% (€18M), with significant constant currency growth offset by currency translation effects.

Guidance, Outlook, Risks, and Unusual Items

• COVID-19 Impact: The pandemic resulted in a net positive impact of €2 million to net income for the six months ended June 30, 2020, due to government relief funds offsetting increased costs and lost revenue. The company expects continued unpredictable expenses and demand fluctuations.
• Cybersecurity Incident: In May 2020, the company's IT environment was attacked, resulting in the illegal publication of patient data in Serbia. Management states there was no material financial impact, but future attacks could disrupt operations.
• Regulatory & Legal:
  • FCPA Settlement: The company is under a non-prosecution agreement with the DOJ and SEC, requiring an independent compliance monitor.
  • Reimbursement: CMS proposed a 2.4% payment increase for large dialysis organizations for CY 2021. The 2% Medicare sequestration is suspended through December 2020.
  • Internal Controls: A material weakness in internal control over financial reporting regarding revenue recognition for fee-for-service arrangements under legal consideration continues to exist as of June 30, 2020.
• Capital Allocation: The company repurchased approximately €366 million of treasury stock in the first half of 2020. Anticipated full-year 2020 capital expenditures are €1.1 to €1.3 billion.

Investor Verification Checklist

• CARES Act Utilization: Verify the extent to which government relief funds (€251M received) have been offset against qualifying costs versus remaining as liabilities.
• Internal Control Remediation: Monitor progress on remediation of the material weakness regarding revenue recognition constraints for legal disputes.
• FCPA Monitor Costs: Track ongoing expenses related to the independent compliance monitor required by the DOJ/SEC settlement.
• Latin America Impairment Risk: Review sensitivity analysis for the Latin America segment, where the recoverable amount exceeds carrying value by only €23 million, indicating high sensitivity to economic downturns.
• Cybersecurity Exposure: Assess potential future costs or reputational damage stemming from the May 2020 data breach.